BRPI0407832A - inibidor de pten ou abridor dos canais maxi-k - Google Patents

inibidor de pten ou abridor dos canais maxi-k

Info

Publication number
BRPI0407832A
BRPI0407832A BRPI0407832-2A BRPI0407832A BRPI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A BR PI0407832 A BRPI0407832 A BR PI0407832A
Authority
BR
Brazil
Prior art keywords
maxi
medicine
pten
opener
channel opener
Prior art date
Application number
BRPI0407832-2A
Other languages
English (en)
Inventor
Ki Whan Hong
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0407832A publication Critical patent/BRPI0407832A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"INIBIDOR DE PTEN OU ABRIDOR DOS CANAIS MAXI-K". A presente invenção refere-se a um novo abridor do PTEN ou um novo abridor de um canal K¬ +¬ ativado por Ca¬ 2+¬ de grande condutância (canal Maxi-K) que compreende como um ingrediente ativo um composto de tetrazolilalcóxi-dihidrocarboestirila da fórmula (1), em que R é cicloalquila, A é um alquileno inferior, e a ligação entre as posições 3 e 4 do núcleo de carboestirila é ligação única ou uma ligação dupla, ou um sal deste, que é útil como um medicamento para a promoção da sobrevivência de células normais, células cerebrais, células cardíacas, e pele, e ainda para a inibição da sepse Gram negativa e migração celular e invasão celular devido à inibição do PTEN e é ainda útil como um medicamento para o tratamento de distúrbios neuronais, por exemplo, um anticonvulsivo, um agente neuroprotetor, um medicamento para o tratamento de edema cerebral regional e enfraquecimento motor neurológico, distúrbios cognitivos, lesão cerebral traumática, doença de Parkinson, epilepsia, enxaqueca e doença de Alzheimer, etc.
BRPI0407832-2A 2003-02-25 2004-02-24 inibidor de pten ou abridor dos canais maxi-k BRPI0407832A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44943503P 2003-02-25 2003-02-25
US44958903P 2003-02-26 2003-02-26
PCT/JP2004/002146 WO2004075897A1 (en) 2003-02-25 2004-02-24 Pten inhibitor or maxi-k channels opener

Publications (1)

Publication Number Publication Date
BRPI0407832A true BRPI0407832A (pt) 2006-02-14

Family

ID=32930512

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407832-2A BRPI0407832A (pt) 2003-02-25 2004-02-24 inibidor de pten ou abridor dos canais maxi-k

Country Status (20)

Country Link
US (3) US7825130B2 (pt)
EP (1) EP1599205B1 (pt)
JP (3) JP4590397B2 (pt)
KR (1) KR101031163B1 (pt)
CN (2) CN1780623B (pt)
AR (1) AR043379A1 (pt)
AT (1) ATE345800T1 (pt)
AU (1) AU2004216340B9 (pt)
BR (1) BRPI0407832A (pt)
CA (1) CA2515590C (pt)
CY (1) CY1106294T1 (pt)
DE (1) DE602004003348T2 (pt)
DK (1) DK1599205T3 (pt)
ES (1) ES2276282T3 (pt)
HK (2) HK1148225A1 (pt)
MX (1) MXPA05008996A (pt)
MY (1) MY136863A (pt)
PT (1) PT1599205E (pt)
TW (1) TWI323660B (pt)
WO (1) WO2004075897A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TW200848041A (en) 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
DK2157973T3 (en) * 2007-05-22 2015-08-17 Univ Juntendo DRUG COMPREHENSIVE A carbostyril derivative donepezil AND TREATMENT Alzheimer's disease
AR067746A1 (es) * 2007-08-02 2009-10-21 Otsuka Pharma Co Ltd Un medicamento para tratar glaucoma que comprende como elemento activo compuesto de ciclodextrina - clatrato de cilostazol
US9259438B2 (en) 2008-01-17 2016-02-16 Kui Liu Methods for in vitro maturation of ovarian follicles
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares
WO2009117387A2 (en) * 2008-03-17 2009-09-24 The Trustees Of Columbia University In The City Of New York Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
AU2009255973B2 (en) * 2008-06-06 2013-08-15 Children's Medical Center Corporation Promoting axon regeneration in the adult CNS through control of protein translation
CA2777628C (en) * 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2013067125A1 (en) 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
CA2876371A1 (en) 2012-06-15 2013-12-19 Foundation For Biomedical Research And Innovation Prophylactic and/or therapeutic agent for mild cognitive impairment
JP2016040542A (ja) * 2014-08-13 2016-03-24 学校法人金沢医科大学 認知症治療薬または認知症治療薬候補物質のスクリーニング方法
JP2017070404A (ja) * 2015-10-06 2017-04-13 アンディ チャオ トイレ床面の清潔な芳香パッド
CN109310688B (zh) 2016-05-19 2023-09-01 国立研究开发法人国立循环器病研究中心 用于预防和/或治疗痴呆症的药物
WO2021230131A1 (ja) * 2020-05-11 2021-11-18 株式会社島津製作所 軽度認知障害治療剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS5649378A (en) * 1979-08-25 1981-05-02 Otsuka Pharmaceut Co Ltd Tetrazolylalkoxycarbostyril derivative
JPH0653666B2 (ja) 1990-10-22 1994-07-20 大塚製薬株式会社 ヒトの糖尿病性知覚障害および末梢神経障害の治療剤
JPH0614444A (ja) * 1992-06-25 1994-01-21 Central Japan Railway Co 電力ケーブル接続部の固定装置
WO1994014444A1 (en) * 1992-12-24 1994-07-07 Otsuka Pharmaceutical Co., Ltd. Psoriasis remedy
JPH06239745A (ja) * 1992-12-24 1994-08-30 Otsuka Pharmaceut Co Ltd 乾癬治療剤
JPH0776584A (ja) 1993-09-07 1995-03-20 Otsuka Pharmaceut Co Ltd 内皮細胞障害抑制剤
JP3944257B2 (ja) 1995-12-07 2007-07-11 大塚製薬株式会社 肝実質細胞増殖因子産生増加剤
US6322524B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Dual riser/single capillary viscometer
US6019735A (en) * 1997-08-28 2000-02-01 Visco Technologies, Inc. Viscosity measuring apparatus and method of use
US6428488B1 (en) * 1997-08-28 2002-08-06 Kenneth Kensey Dual riser/dual capillary viscometer for newtonian and non-newtonian fluids
US6322525B1 (en) * 1997-08-28 2001-11-27 Visco Technologies, Inc. Method of analyzing data from a circulating blood viscometer for determining absolute and effective blood viscosity
BR9908716A (pt) * 1998-05-01 2000-11-21 Neal R Cutler Tratamento de disfunção sexual em certos grupos de pacientes
US6187790B1 (en) * 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6257985B1 (en) * 1999-10-01 2001-07-10 Rexnord Corporation Global shaft coupling
US6484565B2 (en) * 1999-11-12 2002-11-26 Drexel University Single riser/single capillary viscometer using mass detection or column height detection
JP4159224B2 (ja) 2000-02-29 2008-10-01 三洋電機株式会社 食器洗浄機
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener

Also Published As

Publication number Publication date
JP5566482B2 (ja) 2014-08-06
HK1148225A1 (zh) 2011-09-02
DE602004003348T2 (de) 2007-05-31
PT1599205E (pt) 2007-01-31
WO2004075897A1 (en) 2004-09-10
CN101829116A (zh) 2010-09-15
JP5208172B2 (ja) 2013-06-12
US7825130B2 (en) 2010-11-02
JP2006518732A (ja) 2006-08-17
CY1106294T1 (el) 2011-10-12
AU2004216340B9 (en) 2008-09-18
JP2013082735A (ja) 2013-05-09
EP1599205B1 (en) 2006-11-22
CA2515590C (en) 2011-09-13
US20100113515A1 (en) 2010-05-06
TW200501954A (en) 2005-01-16
JP4590397B2 (ja) 2010-12-01
US20060154963A1 (en) 2006-07-13
US8329731B2 (en) 2012-12-11
US20130065921A1 (en) 2013-03-14
CN101829116B (zh) 2015-11-25
DE602004003348D1 (de) 2007-01-04
DK1599205T3 (da) 2007-03-26
CN1780623A (zh) 2006-05-31
MXPA05008996A (es) 2005-10-18
CA2515590A1 (en) 2004-09-10
ATE345800T1 (de) 2006-12-15
HK1091409A1 (en) 2007-01-19
AR043379A1 (es) 2005-07-27
US8653104B2 (en) 2014-02-18
AU2004216340B2 (en) 2008-07-31
ES2276282T3 (es) 2007-06-16
AU2004216340A1 (en) 2004-09-10
KR101031163B1 (ko) 2011-04-27
KR20050098960A (ko) 2005-10-12
TWI323660B (en) 2010-04-21
MY136863A (en) 2008-11-28
CN1780623B (zh) 2011-09-14
EP1599205A1 (en) 2005-11-30
JP2010285456A (ja) 2010-12-24

Similar Documents

Publication Publication Date Title
BRPI0407832A (pt) inibidor de pten ou abridor dos canais maxi-k
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
BRPI0520588A2 (pt) composições farmacêuticas para o tratamento de distúrbios do ouvido interno
JP2005527512A5 (pt)
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CA2547445A1 (en) Systems and methods for altering vestibular biology
BRPI0418195A (pt) aplicação de rotigotina para o tratamento ou a prevenção da perda de neurÈnios dopaminérgicos
BR0012387A (pt) Composição para tratamento de distúrbios de secreção externa
WO2021252538A3 (en) Advantageous benzofuran compositions for mental disorders or enhancement
HK1042655B (zh) 促紅細胞生成素用於生產腦局部缺血藥物的應用
MX2007012794A (es) Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO2010018996A3 (ko) 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
HK1092358A1 (en) Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgloisis
WO2010036052A3 (ko) 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 조성물
CA2864606C (en) Methods of treating and preventing diseases and disorders of the central nervous system
BR0312696A (pt) Tratamento tópico de doenças da pele
BR0207272A (pt) Método de tratamento de doenças ou condições de desmielinação
ITMI20030573A1 (it) Composti ad azione nootropica, loro preparazione,
WO2002062327A3 (en) Method of treating neurological disorders using acetone derivatives
WO2004062616A3 (en) Method of treating cognitive decline due to sleep deprivation and stress
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
IL194346A0 (en) Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.